ProfileGDS5678 / 1416301_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 77% 83% 79% 78% 78% 81% 81% 83% 83% 76% 81% 83% 76% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.5542480
GSM967853U87-EV human glioblastoma xenograft - Control 25.3274777
GSM967854U87-EV human glioblastoma xenograft - Control 36.0879783
GSM967855U87-EV human glioblastoma xenograft - Control 45.6585879
GSM967856U87-EV human glioblastoma xenograft - Control 55.4690478
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.1884578
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.6877781
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.7529181
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.1376883
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.182483
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.0592876
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.8216681
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.0587683
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.0697976